Free Trial

KraneShares MSCI All China Health Care Index ETF Rating

$15.14 -0.07 (-0.46%)
(As of 11/21/2024 ET)

KraneShares MSCI All China Health Care Index ETF Aggregate Rating and Price Target (2024)

MarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.

KURE Aggregate Rating

Buy
3.00

Holdings in KURE have an aggregate rating of Buy based on 13 analyst ratings issued in the past year covering 1 companies (2.0% of the portfolio).

KURE Aggregate Price Target

$15.14
High Prediction$15.14
Average Prediction$15.14
Low Prediction$15.14

Holdings in KURE have an aggregate price target of $15.14 and a range of $15.14 to $15.14 covering 1 companies (2.0% of the portfolio).

KURE Consensus Ratings of Holdings

Strong Buy
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
Moderate Buy
0 Moderate Buy rating(s)
Hold
0 Hold rating(s)
Reduce
0 Reduce rating(s)
Sell
0 Sell rating(s)
Strong Sell
0 Strong Sell rating(s)

Ratings for Stocks Held by KraneShares MSCI All China Health Care Index ETF

 
 
Strong Sell
Sell
Reduce
Hold
Moderate Buy
Buy
Strong Buy

Ratings for the Top 1 KURE Holdings

Weight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)View
Ratings
1.99%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$39.75
-1.0%
1.7657 of 5 stars
3.00$81.46 104.9%13Analyst Revision

This page (NYSEARCA:KURE) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners